by NanoLogix | Mar 18, 2021 | updates
The Company is pleased to announce the achievement of certain milestones in their initial phase of commercialization for the Rapid Viral Assay (RVA). Those are: 1. Successful Detection of irradiated (inactive) COVID-19 virus and its associated Spike Protein. 2....
by NanoLogix | Jun 12, 2020 | updates
NanoLogix is pleased to announce we have received a notification, dated 06/03/20, from the US Patent and Trademark Office stating the application has been granted Prioritized Status under the new COVID-19 Prioritized Examination Pilot Program. “1. THE REQUEST...
by NanoLogix | Jun 3, 2020 | updates
NanoLogix, Inc. (OTC: NNLX), an innovator in the rapid detection and identification of viruses and bacteria, is seeking a partner or partners for obtaining FDA Emergency Use Authorization, if required, and for development and marketing of their sub 1-hour COVID-19...
by NanoLogix | Jun 1, 2020 | updates
Realizing that many of our shareholders are from areas where they may not be aware of news coverage of NanoLogix developments, the Company is pleased to present the following links to articles written and interviews done during the month of May. Warren Tribune:...
by NanoLogix | May 19, 2020 | updates
NanoLogix is pleased to announce the filing of a patent application for use in the rapid testing of the Covid-19 virus. The application was filed under a new program instituted May 14th by the US Patent and Trademark Office. Now that Patent Pending status has been...
by NanoLogix | May 3, 2020 | updates
Last week NanoLogix completed development testing of a unique Coronavirus (COVID-19) detection technology with sub 1-hour results and exceptional sensitivity and accuracy. The technology has the potential to be configured as a Point of Care (POC) and also for...
